Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer

Amritha Nair(Baylor College of Medicine), Thomas F. Westbrook(Baylor College of Medicine), David J. Shields(Pfizer (United States)), Rocío Domínguez-Vidaña(Baylor College of Medicine), Sarah J. Kurley(Baylor College of Medicine), Doug W. Chan(Baylor College of Medicine), Hui Li(University of Maryland, Baltimore), Olivier Lichtarge(Baylor College of Medicine), Carolina Gutiérrez(Baylor College of Medicine), Panagiotis Katsonis(Baylor College of Medicine), Fabio Stossi(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Charles Y. Lin(Kronos Bios (United Kingdom)), Michael T. Lewis(Baylor College of Medicine), Sufeng Mao(Baylor College of Medicine), Lacey E. Dobrolecki(Baylor College of Medicine), Xiao Yu(Shandong University), Chad J. Creighton(Baylor College of Medicine), Julien Dubrulle(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Matthew J. Ellis(Guardant (United States)), Tingting Sun(Northwest University), Jeffrey Tyner(Oregon Health & Science University), David Henke(Baylor College of Medicine), Alexander Renwick(Baylor College of Medicine), Chad A. Shaw(Baylor College of Medicine), Mothaffar F. Rimawi(Baylor College of Medicine), Mayra Orellana(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), James G. Christensen, Ivana Petrović(University of Basel), Bing Zhang(Baylor Genetics), Jin‐Peng Sun(Shandong University), Kenneth L. Scott(Dana-Farber Cancer Institute), Siddhartha Tyagi(Baylor College of Medicine), Earlene M. Schmitt(Baylor College of Medicine), Hsiang-Ching Chung(Baylor College of Medicine)
Nature Medicine
March 26, 2018
Cited by 83


Related Papers